Important Biotech Catalysts For September 12, 2022 - End Of The Day Summary

• The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate XMT-1660 for the treatment of adult patients with advanced or metastatic triple-negative breast cancer (TNBC). Mersana shares traded as high as 1.79 percent, in a range of $7.48 to $7.94 on day volume of 1.34 million shares, closed regular trading session at $7.48. The company shares traded at $7.40, down 1.07 percent in the after-hours trading session.

• The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ:ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome.The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023. ACADIA shares traded as high as 4.95 percent, in a range of $17.33 to $18.24 on day volume of 1.35 million shares, closed regular trading session at $17.91.